List of Excipients in Branded Drug DIAZEPAM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Pharmaceuticals USA Inc	DIAZEPAM	diazepam	0093-6137	ALCOHOL
Teva Pharmaceuticals USA Inc	DIAZEPAM	diazepam	0093-6137	BENZOIC ACID
Teva Pharmaceuticals USA Inc	DIAZEPAM	diazepam	0093-6137	BENZYL ALCOHOL
Teva Pharmaceuticals USA Inc	DIAZEPAM	diazepam	0093-6137	HYPROMELLOSE

Generic Drugs Containing DIAZEPAM

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	diazepam	0054-3188	ANHYDROUS CITRIC ACID
Hikma Pharmaceuticals USA Inc	diazepam	0054-3188	D&C YELLOW NO. 10
Hikma Pharmaceuticals USA Inc	diazepam	0054-3188	FD&C RED NO. 40
Hikma Pharmaceuticals USA Inc	diazepam	0054-3188	POLYETHYLENE GLYCOL 1000

What are the Most Frequently-Used Excipients in DIAZEPAM?

# Of NDCs	Excipient
24	ALCOHOL
8	ALUMINUM OXIDE
8	ANHYDROUS CITRIC ACID
107	ANHYDROUS LACTOSE

Diazepam Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Diazepam is a mature, genericized benzodiazepine with limited opportunity in conventional tablets and injectable products. The strongest commercial opportunities are differentiated delivery systems that improve rescue use, pediatric administration, portability, dose accuracy, and abuse-risk management. Formulation value is concentrated in intranasal, rectal, buccal, and other rapid-delivery products rather than in new diazepam chemistry.

The main excipient priorities are:

1. Avoiding or reducing propylene glycol and ethanol exposure in parenteral and liquid products.
2. Improving nasal mucosal absorption without irritation.
3. Masking bitterness and reducing administration errors in pediatric and caregiver settings.
4. Supporting preservative-free, unit-dose, portable rescue products.
5. Creating formulation and device barriers that are more defensible than conventional tablet excipients.

What excipients are used in approved diazepam products?

Approved diazepam products use different excipient strategies according to route of administration. The route determines the principal technical and commercial constraints.

Product type	Typical dosage form	Representative excipient strategy	Primary commercial issue
Immediate-release tablets	2 mg, 5 mg, 10 mg tablets	Lactose or other diluent, starch, colloidal silicon dioxide, magnesium stearate, colorants	Low differentiation and heavy generic competition
Oral solution or concentrate	Usually 1 mg/mL or 5 mg/mL	Propylene glycol, ethanol, water, sweeteners, sodium benzoate or benzoic acid	Taste, alcohol exposure, dosing errors and preservative tolerance
Injection	5 mg/mL solution	High levels of propylene glycol, ethanol, benzyl alcohol or related preservative systems depending on product	Injection-site tolerability, toxicity concerns and excipient burden
Rectal gel	Unit-dose prefilled applicator	Carbomer or related viscosity modifier, solvent system, preservative and pH control	Administration acceptability, device cost and established branded competition
Intranasal spray	Metered-dose nasal solution	Solubilizer, absorption enhancer, buffering system and stabilizer	Nasal irritation, dose uniformity, IP protection and device performance

Specific excipient compositions vary by manufacturer and jurisdiction. FDA-approved labeling and DailyMed should control any product-specific assessment (U.S. Food and Drug Administration [FDA], n.d.-a; National Library of Medicine, n.d.).

Which diazepam formulations have the strongest commercial potential?

Intranasal diazepam has the strongest current commercial position among differentiated formulations. Valtoco, marketed by Neurelis, was approved by FDA in 2020 for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients six years of age and older (FDA, 2020). Its commercial value comes from caregiver administration, portability, needle-free delivery and avoidance of rectal administration.

Rectal diazepam remains clinically relevant, particularly through Diastat and generic equivalents, but it has weaker long-term differentiation. Rectal administration has greater social and practical barriers than nasal delivery. Generic entry and established clinical familiarity limit pricing power.

Oral liquid diazepam has a narrower opportunity. It is useful for patients who cannot swallow tablets, but the conventional solvent systems create taste, alcohol, propylene glycol and dosing challenges. A formulation with improved palatability, lower alcohol content, and a stable preservative-free unit-dose presentation could support institutional and pediatric opportunities.

Injectable diazepam has limited formulation upside. The active ingredient is highly lipophilic and requires solvent systems that can create tolerability and safety concerns. A replacement product based on a safer solubilization platform could have value in emergency medicine, procedural sedation and veterinary care, but the development burden is materially higher than for an oral product.

What excipient strategy should be used for diazepam oral products?

Tablets

Conventional diazepam tablets are a low-value formulation target. The formulation is technically simple, and numerous manufacturers have supplied generic products. New tablet products need a defined clinical or operational advantage, such as:

• Orally disintegrating tablets for patients with dysphagia.
• Low-dose tablets with improved dose uniformity for geriatric or pediatric titration.
• Multiparticulate sachets or sprinkle formulations.
• Taste-masked granules for administration with soft food.
• Abuse-deterrent tablets with physical or chemical resistance to crushing and solvent extraction.

An orally disintegrating tablet could use mannitol, crospovidone, microcrystalline cellulose, low-substituted hydroxypropyl cellulose, and a low-level lubricant. The main technical issue is diazepam’s poor water solubility. Rapid disintegration does not necessarily produce rapid systemic absorption unless the formulation controls wetting, particle size and dissolution.

Taste masking is commercially important because diazepam is bitter and benzodiazepines are often administered to children or patients with neurological disorders. Polymer coating, ion-exchange complexes, lipid-based granules, and multiparticulate encapsulation are more defensible than simply adding a sweetener.

Oral liquids

The central formulation objective is to reduce dependence on ethanol and propylene glycol while preserving solubility and chemical stability. Potential approaches include:

• Cosolvent reduction through nanosizing or amorphous solid dispersion.
• Cyclodextrin complexation.
• Lipid-based self-emulsifying systems.
• Surfactant-assisted solutions or suspensions.
• Taste-masked suspensions with controlled sedimentation.
• Unit-dose oral syringes or stick packs.

Cyclodextrins can improve apparent solubility, but the choice of cyclodextrin must account for route, dose, renal exposure and regulatory precedent. A suspension may reduce solvent burden but introduces dose-uniformity, redispersibility and microbial-control requirements.

For pediatric use, a low-alcohol or alcohol-free product with a calibrated oral syringe is more commercially meaningful than a minor change in flavor. The product should minimize caregiver calculation, avoid multidose bottle contamination, and present diazepam concentration in a way that reduces medication errors.

What excipients are most important for injectable diazepam?

Injectable diazepam is constrained by solubility. Commercial products commonly rely on propylene glycol and ethanol to keep diazepam in solution. These solvents can contribute to pain on injection, phlebitis, tissue injury, hypotension, metabolic burden and toxicity concerns, especially in neonates, children, older adults and patients receiving repeated doses.

A next-generation injectable strategy would seek to:

1. Lower propylene glycol concentration.
2. Reduce ethanol concentration.
3. Improve aqueous solubility through complexation or colloidal delivery.
4. Maintain chemical stability during storage.
5. Preserve compatibility with commonly used infusion and injection materials.
6. Avoid precipitation after dilution.

Potential platforms include cyclodextrin complexes, mixed micelles, liposomes, polymeric nanoparticles and prodrug approaches. A prodrug would generally create a new chemical entity rather than a pure excipient-led product and would require a more extensive clinical and regulatory program.

Commercial value depends on a measurable benefit. A formulation that reduces injection pain or excipient toxicity without changing clinical dosing could support hospital contracting. A product with only a different solvent ratio would face weak differentiation and rapid substitution.

How can excipients improve diazepam intranasal delivery?

Intranasal diazepam requires a formulation that balances solubility, absorption, dose reproducibility and nasal tolerability. Because diazepam is lipophilic and poorly water-soluble, the product must use a solvent, cosolvent, surfactant, complexing agent, or absorption-enhancing system.

The most relevant excipient functions are:

• Solubilization of diazepam at the target dose.
• Rapid wetting and spreading across the nasal mucosa.
• Controlled enhancement of epithelial permeability.
• Buffering within a tolerable nasal pH range.
• Protection against precipitation during storage.
• Reduction of post-dose runoff and swallowing.
• Compatibility with the metered-dose device.

Dodecyl maltoside and related surfactant-based absorption enhancers have been used in intranasal drug-delivery platforms. Their commercial value depends on maintaining a favorable balance between enhancement and local tolerability. Excessive surfactant concentration can cause irritation, epithelial disruption or unacceptable sensory effects.

The most defensible intranasal IP usually combines several claim categories:

• Diazepam concentration ranges.
• Specific absorption enhancers.
• Solvent and buffer ratios.
• Dose volume and spray pattern.
• Device geometry.
• Priming and actuation performance.
• Pharmacokinetic exposure.
• Stability and container-closure compatibility.

A generic competitor may be able to avoid a narrow formulation claim by changing the enhancer, concentration or device. Broad patents covering the overall nasal-delivery concept have greater value, but they are more vulnerable to prior-art challenges.

What patents protect diazepam formulations?

The original composition-of-matter protection for diazepam expired decades ago. Conventional tablet, oral solution and injectable products therefore have limited patent-based exclusivity. Their competitive barriers are manufacturing scale, regulatory filings, supply reliability and distribution.

Modern protection is concentrated in delivery-specific patents. These may cover:

• Intranasal diazepam formulations.
• Absorption-enhancer systems.
• Metered-dose nasal devices.
• Rectal gel compositions and applicators.
• Unit-dose packaging.
• Treatment methods for seizure clusters.
• Pediatric dosing regimens.
• Manufacturing and filling processes.

Valtoco has product-specific intellectual-property protection associated with its formulation, delivery system and use. The relevant Orange Book record should be reviewed for current listed patents, expiry dates, pediatric extensions and any regulatory exclusivity (FDA, n.d.-b). Patent expiration dates can differ by patent, terminal disclaimer, patent-term adjustment, pediatric extension and litigation outcome.

Diastat’s core formulation and delivery protection is substantially older. The product is exposed to generic competition, although device design, manufacturing know-how and regulatory execution can still affect market access.

When does diazepam lose exclusivity?

Diazepam itself has already lost chemical and basic formulation exclusivity. The practical market position is divided by dosage form:

Segment	Exclusivity position	Competitive outlook
Tablets	Genericized	Price competition and broad supplier base
Oral solution	Genericized, with formulation-specific variation	Opportunity for better taste, packaging and solvent profile
Injection	Genericized	Limited differentiation unless excipient burden is materially reduced
Rectal gel	Generic competition exists or is developing depending on market	Lower-cost alternatives constrain pricing
Intranasal spray	Branded formulation and device IP provide stronger protection	Highest near-term value, but patent and regulatory challenges are possible

FDA product-specific exclusivity is separate from patent protection. A new diazepam formulation may receive three years of exclusivity if it contains a previously approved active ingredient and approval relies on new clinical investigations essential to approval. Orphan-drug exclusivity may apply only if the product and indication meet statutory requirements. Valtoco’s commercial protection therefore depends on the interaction of patents, regulatory exclusivity and the difficulty of demonstrating bioequivalence for a complex nasal product.

What is the Orange Book status of diazepam?

The Orange Book includes approved drug products and, where applicable, listed patents and exclusivity information. Conventional generic diazepam tablets, solutions and injections generally have no meaningful remaining exclusivity tied to diazepam’s original approval. Branded delivery systems may have listed patents that cover the formulation, device, method of use or combinations of these elements (FDA, n.d.-b).

For an investment or licensing decision, the relevant review is product-specific rather than molecule-wide. It should compare:

• NDA versus ANDA status.
• Listed patents by dosage form.
• Patent expiration and pediatric-extension dates.
• Therapeutic-equivalence codes.
• Approved strengths and routes.
• Reference-listed-drug status.
• Any 30-month stay associated with Paragraph IV litigation.

Which companies are challenging diazepam products?

Generic manufacturers have long competed in diazepam tablets, oral solutions and injections. The most important competitive threat to branded rescue products is a generic or authorized-generic nasal or rectal product that can demonstrate therapeutic equivalence or otherwise obtain FDA approval under the applicable pathway.

Paragraph IV risk is highest for intranasal diazepam because a challenger may contest formulation, device, method-of-use or patent-validity claims. A nasal product can also face technical barriers involving comparative pharmacokinetics, spray performance, device reliability and local tolerability. These barriers raise development costs but do not eliminate eventual generic risk.

No biosimilar pathway applies. Diazepam is a small-molecule drug, not a biologic. Competitive entry occurs through ANDA, 505(b)(2), or a new NDA pathway rather than through a biosimilar application.

What patent litigation and settlement issues affect diazepam?

The principal litigation exposure for a branded diazepam nasal product is an ANDA Paragraph IV challenge. The potential outcomes are:

1. Patent litigation delays approval or launch.
2. Settlement permits an agreed generic entry date.
3. The challenger prevails and launches before patent expiry.
4. The branded company narrows claims or abandons enforcement.
5. FDA approval proceeds after patent expiry or non-infringement certification.

Conventional diazepam tablets and injections have limited litigation value because their core patents are expired. Litigation economics are more relevant for nasal delivery, device combinations and seizure-cluster methods.

A settlement can preserve branded revenue while establishing a controlled generic-entry date. Its value depends on the remaining patent term, the probability of invalidity, the size of the rescue-market opportunity and the presence of competing products.

What commercial opportunities exist for diazepam excipients?

The strongest opportunities are product platforms rather than commodity excipients.

Intranasal rescue products

An excipient supplier can license a nasal absorption-enhancement platform to a diazepam developer. The target value proposition is a lower-volume spray with rapid and consistent exposure, low irritation, and a scalable manufacturing process.

Pediatric oral liquids

A low-alcohol, low-solvent, taste-masked diazepam liquid could compete in pediatric neurology, long-term care and home rescue settings. Packaging and dosing accuracy may create more value than the active formulation alone.

Preservative-free unit-dose products

Single-use oral or nasal presentations can reduce contamination risk, caregiver dosing errors and storage complexity. Unit-dose packaging also supports hospital, ambulance and institutional channels.

Injectable reformulation

A lower-excipient injectable product could target emergency departments, procedural sedation and veterinary medicine. The opportunity is technically attractive but carries the highest development and regulatory risk.

Abuse-deterrent formulations

Diazepam is a Schedule IV controlled substance in the United States and has recognized dependence and misuse risks (U.S. Drug Enforcement Administration, n.d.). Abuse-deterrent excipient systems could support payer and institutional differentiation, although they may increase cost and do not eliminate clinical misuse.

How strong is the diazepam patent estate?

The diazepam patent estate is weak for the active ingredient and conventional dosage forms but stronger for newer delivery systems. Patent strength depends on claim breadth, prior art, enablement, device integration and the ability of a generic competitor to design around the claims.

Patent category	Relative strength	Commercial relevance
Diazepam composition of matter	Very low	Expired
Conventional tablet excipients	Very low	Easily designed around
Oral taste masking	Low to moderate	Useful if tied to measurable performance
Injectable solvent replacement	Moderate	Depends on clinical advantage
Rectal gel and applicator	Moderate	Mature technology with generic pressure
Intranasal formulation and device	Moderate to strong	Main source of branded protection
Method of treating seizure clusters	Variable	Vulnerable to claim construction and prior art
Manufacturing process	Moderate	Can protect supply advantages but is difficult to detect in litigation

Key Takeaways

• Diazepam’s core patent protection has expired; commercial value lies in differentiated delivery.
• Intranasal diazepam offers the strongest opportunity for formulation, device and method-of-use IP.
• The best excipient strategy for oral liquids is solvent reduction combined with taste masking and unit-dose packaging.
• Injectable reformulation is technically valuable but faces substantial solubility and clinical-development barriers.
• Tablets offer limited return unless they add a clear benefit such as rapid disintegration, pediatric dosing, or abuse deterrence.
• No biosimilar pathway applies to diazepam.
• Paragraph IV risk is concentrated in newer nasal and device-based products.
• Excipient suppliers have the greatest licensing opportunity in absorption enhancement, solubilization, taste masking and preservative-free unit-dose systems.

FAQs

Can diazepam be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but rapid disintegration alone does not ensure rapid absorption because diazepam has low aqueous solubility. The formulation would need improved wetting, dissolution and taste control.

Is propylene glycol essential in diazepam injection?

Propylene glycol has historically been used to solubilize diazepam in injectable products, but it is not the only possible platform. Cyclodextrin complexes, micellar systems and other solubilization approaches could reduce solvent exposure if they meet stability and safety requirements.

Can a new diazepam nasal spray receive regulatory exclusivity?

Yes. A reformulated diazepam product may qualify for regulatory exclusivity if it meets the statutory requirements for new clinical investigations, orphan designation or another applicable pathway. Patent protection and FDA exclusivity are separate rights.

What is the main manufacturing barrier for intranasal diazepam?

The main barriers are consistent drug loading, prevention of precipitation, metered-dose accuracy, spray-pattern control, container-closure compatibility and nasal tolerability. These requirements make intranasal products more difficult to replicate than tablets.

Is veterinary diazepam a separate patent opportunity?

Veterinary use can support a separate commercial strategy, particularly for injectable, rectal or intranasal rescue products. The principal barriers are still generic competition, controlled-substance regulation, species-specific dosing and proof of formulation safety.

References

1. National Library of Medicine. (n.d.). DailyMed: Diazepam product labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling

3. U.S. Food and Drug Administration. (2020). FDA approves first nasal spray medication for acute treatment of seizure clusters. https://www.fda.gov/

4. U.S. Food and Drug Administration. (n.d.-a). Diazepam injection, oral solution, tablet, and rectal gel labeling. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm